Wednesday's Small-Cap Winners & Losers
Targeted Genetics (TGEN) was another big health-care loser. Shares of the Seattle biotech company slid 20.5% to $2.09 after the FDA put development of its investigational inflammatory-arthritis therapy, tgAAC94, on clinical hold "as a precautionary measure ... due to the uncertainty of the cause of a serious adverse event that occurred in one subject." The compound had been in phase I/II testing.
Away from health stocks, Jakks Pacific (JAKK) was hurting after the Malibu, Calif., toy company whittled its second-quarter income down to $5 million, or 17 cents a share, from 22 cents a share last year. Wall Street had expected a year-over-year rise to 25 cents a share. Jakks stock was losing $4.52, or 15.1%, to $25.40.
Meanwhile, France-based telecom company Wavecom (WVCM) plunged more than 20% even though second-quarter income vaulted to $6.9 million (5 million euros), or 41 cents a share, compared with about a penny a share last year. Shares were losing $7.39 to $29.20.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV